1. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Journal Article (1370)
  2. Meeting Abstract (1200)
  3. Review (55)
  4. Editorial (43)
  5. Book Section (36)
  6. Research Letter (34)
  7. Correspondence (9)
  8. Conference Paper (7)
  9. Book Whole (6)
  10. Miscellaneous (6)
  11. Guidelines (4)
Groups
  1. Center for Hematologic Malignancies (2770)
  2. Executive Committee, Center for Hematologic Malignancies (2770)
  3. GSK Faculty (2459)
  4. Department of Medicine (2415)
  5. Hematologic Malignancies, Division of (2358)
  6. Human Oncology and Pathogenesis Program (1333)

More Groups

People
  1. Ross Levine (774)
  2. Marcel Van Den Brink (616)
  3. Omar Abdel-Wahab (573)
  4. Anas Younes (319)
  5. Scott Lowe (249)
  6. Charles Sawyers (225)

More People

Years
  1. 2025 (30)
  2. 2024 (107)
  3. 2023 (176)
  4. 2022 (184)
  5. 2021 (153)
  6. 2020 (207)

More Years

Publications
  1. Blood (782)
  2. Biology of Blood and Marrow Transplantation (136)
  3. Cancer Research (123)
  4. Journal of Clinical Oncology (93)
  5. Haematologica (59)
  6. Cancer Cell (58)

More Publications

Publishers
  1. American Society of Hematology (845)
  2. Nature Publishing Group (338)
  3. American Association for Cancer Research (253)
  4. Elsevier Inc. (215)
  5. Cell Press (160)
  6. American Society of Clinical Oncology (103)

More Publishers

Results (2770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TPX-0005 (Repotrectinib), a next-generation ALK/ROS1/NTRK1-3 inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models
    Meeting Abstract

    O'Donohue, T.; Ibáñez, G.; Mauguen, A.; Siddiquee, A.; Rosales, N.; Calder, P.; Ndengu, A.; Roberts, S.; Dela Cruz, F.; Kung, A.
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • A systems biology approach to reprogramming drug-resistant breast cancer stem-like cells
    Meeting Abstract

    Worley, J.; Ding, H.; Noh, H.; Paull, E.; Bush, E.; Dalerba, P.; Sims, P.; Dela Cruz, F.; Kung, A.; Califano, A.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • CHD1-loss promotes tumor heterogeneity and therapy resistance in prostate cancer
    Meeting Abstract

    Zhang, Z.; Zhou, C.; Li, X.; Sawyers, C.; Mu, P.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Identification of the cells of origin and tumor heterogeneity in neuroendocrine prostate cancer (NEPC) by single-cell analysis
    Meeting Abstract

    Zhao, J. L.; Zaidi, S.; Chan, J.; Wadosky, K.; Karthaus, W.; Choi, D.; Agudelo Rivera, A.; Gopalan, A.; Rathkopf, D.; Carver, B.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • MYC influences metastatic heterogeneity in pancreatic cancer
    Meeting Abstract

    Maddipati, R.; Norgard, R. J.; Baslan, T.; Rathi, K. S.; Zhang, A.; Raman, P.; Wengyn, M. D.; Yamazoe, T.; Li, J.; Balli, D.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York
    Meeting Abstract

    Hubert, B.; Froeling, F.; Arora, K.; Chu, T.; Robine, N.; Zody, M.; Oschwald, D.; Varmus, H.; Sawyers, C.; Tuveson, D.
    Cancer Epidemiology Biomarkers and Prevention (2020)

    Fulltext@MSK | Save
  • Sanjiv "Sam" Gambhir, MD, PhD: In memoriam (1962-2020)
    Miscellaneous

    Wu, A. M.; Iagaru, A.; Herschman, H.; Weissleder, R.; Sawyers, C. L.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2(V617F)-mutant MPN
    Journal Article

    Pastore, F.; Bhagwat, N.; Pastore, A.; Radzisheuskaya, A.; Karzai, A.; Krishnan, A.; Li, B.; Bowman, R. L.; Xiao, W.; Viny, A. D.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis
    Journal Article

    Bolton, K. L.; Ptashkin, R. N.; Gao, T.; Braunstein, L.; Devlin, S. M.; Kelly, D.; Patel, M.; Berthon, A.; Syed, A.; Yabe, M.; more...
    Nature Genetics (2020)

    Fulltext@MSK | Save
  • Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy
    Journal Article

    Straus, D.; Collins, G.; Walewski, J.; Zinzani, P. L.; Grigg, A.; Sureda, A.; Illes, A.; Kim, T. M.; Alekseev, S.; Specht, L.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save